二肽基肽酶-4抑制剂联合阿卡波糖对老年2型糖尿病患者血糖控制及体重指数的影响

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (36 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical efficacy of dipeptidyl peptidase-4 inhibitors combined with acarbose in the treatment of elderly patients with type 2 diabetes mellitus （T2DM）.Methods A total of 108 cases of T2DM patients in our hospital from September 2015 to October 2017 were selected,and divided into the observation group and the control group according to the random number table method,with 54 cases in each group.On the basis of routine diet and exercise intervention,the control group was treated with acarbose,and the observation group was treated with acarbose+dipeptidyl peptidase-4 inhibitors (sitagliptin).Both groups were treated for 12 weeks.The blood glucose level[fasting blood glucose(FBG),postprandial 2 h blood glucose(2h PG),glycosylated hemoglobin(HbA1c)],body mass index (BMI)and incidence of adverse reactions during treatment were compared between the two groups before and after treatment.Results After treatment,the levels of FBG,2 h PG and HbA1c were lower than those before treatment in two groups(P<0.05),and the observation group was lower than the control group(P<0.05).After treatment,the BMI in the observation group was lower than that before the treatment(P<0.05),but there were no significant changes in the control group(P>0.05),and the BMI in the observation group was lower than that in the control group(P<0.05).There were no significant differences in the incidence of flatulence,diarrhea and nasopharyngitis in the observation group compared with the control group during the treatment(P>0.05).Conclusion Dipeptidyl peptidase-4 inhibitors combined with acarbose in the treatment of elderly T2DM is beneficial to the control of blood sugar and the decrease of BMI,and it has high safety.

Key words： Type 2 diabetes mellitus Dipeptidyl peptidase-4 inhibitors Acarbose Blood glucose control Body mass index

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Yi
	CHANG Hai-ying

Cite this article:

LI Yi,CHANG Hai-ying. Effect of Dipeptidyl Peptidase-4 inhibitors combined with Acarbose on blood glucose control and body mass index of elderly patients with type 2 diabetes mellitus[J]. 中国当代医药, 2018, 25(26): 66-68.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I26/66

[1]	梁彩虹，胡庆芬.阿卡波糖与诺和锐30对T2DM患者CGSM参数、血糖达标率的影响[J].中国医药导刊，2017，19（7）：723-724.
[2]	廖淑金，黄萍，傅明捷，等.老年2型糖尿病患者低血糖特征的临床研究[J].中国糖尿病杂志，2016，24（3）：205-209.
[3]	顾丽萍，顾鸣宇，严率，等.二肽基肽酶-4抑制剂对2型糖尿病患者血糖和胰岛功能的影响[J].中国糖尿病杂志，2014，22（10）：883-885.
[4]	李丽，王鹏远，池莲祥，等.西格列汀对T2DM患者胰岛β细胞功能和细胞脂肪因子的影响[J].中国热带医学，2015，15（11）：1402-1403.
[5]	中华医学会糖尿病学分会.中国2型糖尿病防治指南（2013年版）[J].中华内分泌代谢杂志，2014，30（10）：447-498.
[6]	孙静，罗仁.我国医院糖尿病药物治疗及基本药物应用[J].中国药房，2016，27（24）：3313-3319.
[7]	刘黎芳.两种胰岛素联合用药治疗血糖控制不佳2型糖尿病的临床效果观察[J].山西医药杂志，2016，45（14）：1689-1691.
[8]	王秀艳，潘天荣，钟兴，等.西格列汀联合二甲双胍治疗2型糖尿病的疗效及对胰岛功能的影响[J].中国糖尿病杂志，2014，6（6）：382-385.
[9]	杨光，类延娜.二肽基肽酶-4抑制剂非胰高血糖素样肽-1 依赖多效性及其机制探讨[J].中国循环杂志，2017，32（3）：297-300.
[10]	刘湘茹，杨斌，李玥，等.二肽基肽酶4抑制剂在2型糖尿病治疗中的价值[J].中国综合临床，2017，33（2）：119-122.
[11]	夏青松，石瑾.治疗2型糖尿病的新型降糖药物二肽基肽酶-4 抑制药概述[J].药物流行病学杂志，2015，24（5）：311-314.
[12]	祝菁菁，陈文.西格列汀治疗2型糖尿病的药物经济学研究[J].中国药房，2016，27（2）：157-162.
[13]	季文.阿卡波糖联合西格列汀治疗2型糖尿病的临床观察[J].中国药物与临床，2014，14（12）：1722-1724.
[14]	敬仁芝，曹晓红.磷酸西格列汀联合阿卡波糖对老年2型糖尿病患者血糖、血脂及GLUT4水平的影响[J].中国药房，2017，28（9）：1204-1207.
[15]	庞静，李霞，徐杰，等.西格列汀联合阿卡波糖治疗Ⅱ型糖尿病对脂代谢紊乱与胰岛素抵抗的影响[J].西部医学，2017，29（10）：1373-1376.